From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...

The Food and Drug Administration is expected to approve the first new type of drug for schizophrenia in decades. Called KarXT, the medicine appears to be effective, but its main advantage over current ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually.

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia.